COVID-IP: staring down the Bayh-Dole Act with 2020 vision

Area of Science:

• Biomedical Innovation
• Public Health Policy
• Intellectual Property Law

Background:

• The COVID-19 pandemic highlights uncertainties in prevention, detection, and treatment timelines.
• Concerns exist regarding the cost of approved products and access barriers imposed by the patent system.
• Collaborations between industry, government, and academia are driving discovery efforts.

Purpose of the Study:

• To examine the implications of the Bayh-Dole Act on innovation and access to medical products.
• To analyze the calls for utilizing federal "march-in rights" during the COVID-19 pandemic.
• To reflect on the purpose and impact of the Bayh-Dole Act in the context of public health.

Main Methods:

• Review of the Bayh-Dole Act and its legislative history.
• Analysis of current discourse surrounding government march-in rights.
• Examination of patent law's role in accessing therapeutic compounds, delivery methods, and diagnostics.

Main Results:

• The Bayh-Dole Act has shaped patent protections for federally funded research for 40 years.
• The COVID-19 crisis has intensified debate over innovation incentives versus public access.
• Patent rights significantly influence the cost and accessibility of essential medical innovations.

Conclusions:

• The COVID-19 pandemic presents a critical juncture to reassess the Bayh-Dole Act's balance between innovation and accessibility.
• Governmental march-in rights are being considered as a mechanism to mitigate patent monopolization and pricing concerns.
• The long-term implications for public health access hinge on the effective management of intellectual property rights for pandemic-related innovations.